Adaptimmune Therapeutics plc Key Executives
This section highlights Adaptimmune Therapeutics plc's key executives, including their titles and compensation details.
Find Contacts at Adaptimmune Therapeutics plc
(Showing 0 of )
Adaptimmune Therapeutics plc Earnings
This section highlights Adaptimmune Therapeutics plc's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-03-20 | N/A | N/A |
| Read Transcript | Q3 | 2024 | 2024-11-13 | $-0.17 | $-0.07 |
| Read Transcript | Q2 | 2024 | 2024-08-12 | $-0.07 | $0.24 |
| Read Transcript | Q1 | 2024 | 2024-05-15 | $-0.16 | $-0.18 |
| Read Transcript | Q4 | 2023 | 2024-03-06 | $-0.12 | $-0.24 |
| Read Transcript | Q3 | 2023 | 2023-11-08 | $-0.20 | $-0.20 |
| Read Transcript | Q2 | 2023 | 2023-08-09 | $-0.17 | $-0.21 |
| Read Transcript | Q1 | 2023 | 2023-05-12 | $-0.19 | $0.01 |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
$0.27
Stock Price
$68.23M
Market Cap
506
Employees
Abingdon, None
Location
Financial Statements
Access annual & quarterly financial statements for Adaptimmune Therapeutics plc, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $178.03M | $60.28M | $27.15M | $6.15M | $3.96M |
| Cost of Revenue | $70.00K | $9.86M | $127.73M | $111.09M | $91.57M |
| Gross Profit | $177.96M | $50.42M | $-100.58M | $-104.94M | $-87.61M |
| Gross Profit Ratio | 99.96% | 83.65% | -370.48% | -1706.64% | -2213.49% |
| Research and Development Expenses | $149.06M | $126.51M | $127.73M | $111.09M | $91.57M |
| General and Administrative Expenses | $80.81M | $71.81M | $63.39M | $57.30M | $45.80M |
| Selling and Marketing Expenses | $506.00K | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $81.31M | $71.81M | $63.39M | $57.30M | $45.80M |
| Other Expenses | $16.35M | $- | $-536.00K | $3.85M | $1.16M |
| Operating Expenses | $246.72M | $188.42M | $191.11M | $168.40M | $137.36M |
| Cost and Expenses | $246.79M | $198.28M | $191.11M | $168.40M | $137.36M |
| Interest Income | $6.60M | $5.96M | $1.54M | $1.09M | $2.31M |
| Interest Expense | $3.35M | $- | $- | $- | $- |
| Depreciation and Amortization | $11.22M | $9.84M | $6.07M | $6.57M | $7.65M |
| EBITDA | $-52.66M | $-128.20M | $-155.59M | $-155.68M | $-125.81M |
| EBITDA Ratio | -29.58% | -212.67% | -573.13% | -2531.78% | -3178.65% |
| Operating Income | $-68.76M | $-138.04M | $-163.97M | $-162.25M | $-133.41M |
| Operating Income Ratio | -38.62% | -228.99% | -603.97% | -2638.58% | -3370.52% |
| Total Other Income Expenses Net | $1.52M | $25.50M | $-1.29M | $4.95M | $3.48M |
| Income Before Tax | $-67.24M | $-112.53M | $-162.96M | $-157.30M | $-129.93M |
| Income Before Tax Ratio | -37.77% | -186.68% | -600.26% | -2558.12% | -3282.72% |
| Income Tax Expense | $3.58M | $1.34M | $2.50M | $791.00K | $162.00K |
| Net Income | $-70.81M | $-113.87M | $-165.46M | $-158.09M | $-130.09M |
| Net Income Ratio | -39.78% | -188.90% | -609.46% | -2570.99% | -3286.81% |
| EPS | $-0.28 | $-0.57 | $-1.02 | $-1.02 | $-0.90 |
| EPS Diluted | $-0.28 | $-0.57 | $-1.02 | $-1.02 | $-0.90 |
| Weighted Average Shares Outstanding | 252.30M | 201.07M | 161.21M | 155.81M | 142.46M |
| Weighted Average Shares Outstanding Diluted | 252.30M | 201.07M | 161.21M | 155.81M | 142.46M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.22M | $40.90M | $128.23M | $5.68M | $233.01K | $7.32M | $5.13M | $47.60M | $11.03M | $7.01M | $5.54M | $3.58M | $1.42M | $1.20M | $3.10M | $434.00K | $1.50M | $1.19M | $502.00K | $761.00K |
| Cost of Revenue | $- | $- | $2.60M | $2.83M | $2.87M | $2.88M | $2.24M | $1.86M | $23.05M | $33.18M | $34.74M | $36.75M | $29.50M | $28.21M | $28.87M | $24.51M | $25.78M | $24.07M | $20.46M | $21.26M |
| Gross Profit | $3.22M | $40.90M | $125.63M | $2.85M | $-2.64M | $4.44M | $2.89M | $45.74M | $-12.02M | $-26.18M | $-29.20M | $-33.18M | $-28.09M | $-27.01M | $-25.77M | $-24.07M | $-24.27M | $-22.87M | $-19.96M | $-20.50M |
| Gross Profit Ratio | 100.00% | 100.00% | 97.97% | 50.19% | -1133.77% | 60.72% | 56.35% | 96.09% | -109.03% | -373.56% | -527.30% | -928.03% | -1982.22% | -2245.05% | -832.73% | -5546.54% | -1616.18% | -1917.35% | -3975.70% | -2694.22% |
| Research and Development Expenses | $39.10M | $34.30M | $40.45M | $35.21M | $37.23M | $37.79M | $29.96M | $25.55M | $23.05M | $33.18M | $34.74M | $36.75M | $29.50M | $28.21M | $28.87M | $24.51M | $25.78M | $24.07M | $20.46M | $21.26M |
| General and Administrative Expenses | $20.71M | $21.28M | $19.08M | $19.73M | $16.88M | $16.16M | $20.07M | $20.40M | $15.22M | $16.82M | $16.89M | $16.80M | $14.78M | $15.17M | $14.99M | $13.82M | $13.24M | $13.00M | $10.29M | $9.26M |
| Selling and Marketing Expenses | $506.00K | $- | $-2.72M | $- | $-2.73M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $21.22M | $21.28M | $16.36M | $19.73M | $14.15M | $16.16M | $20.07M | $20.40M | $15.22M | $16.82M | $16.89M | $16.80M | $14.78M | $15.17M | $14.99M | $13.82M | $13.24M | $13.00M | $10.29M | $9.26M |
| Other Expenses | $16.42M | $- | $- | $-61.00K | $-313.00K | $-324.00K | $501.00K | $-671.00K | $-1.54M | $1.64M | $-655.00K | $12.00K | $4.04M | $-237.00K | $54.00K | $-1.00K | $414.00K | $-1.69M | $-567.00K | $-152.00K |
| Operating Expenses | $76.74M | $55.58M | $59.53M | $54.94M | $51.38M | $53.95M | $50.04M | $45.95M | $38.27M | $50.00M | $49.29M | $53.56M | $44.28M | $43.38M | $42.41M | $38.32M | $39.02M | $37.07M | $30.75M | $30.52M |
| Cost and Expenses | $76.74M | $55.58M | $59.53M | $54.94M | $54.25M | $53.95M | $50.04M | $45.95M | $38.27M | $50.00M | $49.29M | $53.56M | $44.28M | $43.38M | $42.41M | $38.32M | $39.02M | $37.07M | $30.75M | $30.52M |
| Interest Income | $1.78M | $2.10M | $1.38M | $1.34M | $1.61M | $2.15M | $1.54M | $676.00K | $523.00K | $324.00K | $357.00K | $338.00K | $179.00K | $225.00K | $266.00K | $425.00K | $538.00K | $2.15M | $1.15M | $730.00K |
| Interest Expense | $1.71M | $1.11M | $526.00K | $- | $5.00K | $- | $- | $- | $1.01M | $324.00K | $- | $338.00K | $179.00K | $225.00K | $266.00K | $425.00K | $- | $2.15M | $1.15M | $730.00K |
| Depreciation and Amortization | $2.83M | $2.82M | $2.75M | $2.83M | $2.87M | $2.88M | $2.24M | $1.86M | $1.45M | $1.48M | $1.54M | $1.59M | $2.24M | $1.45M | $1.44M | $1.44M | $1.73M | $1.82M | $2.16M | $1.89M |
| EBITDA | $-67.97M | $-12.86M | $71.01M | $-46.43M | $-49.85M | $-43.74M | $-20.97M | $-1.86M | $-23.51M | $-41.50M | $-42.20M | $-48.39M | $-42.86M | $-40.73M | $-37.87M | $-36.45M | $-40.95M | $-34.31M | $-28.38M | $-28.05M |
| EBITDA Ratio | -2109.68% | -31.44% | 55.38% | -817.74% | -21393.55% | -597.64% | -408.83% | -3.90% | -213.17% | -592.25% | -762.01% | -1353.45% | -3024.98% | -3385.45% | -1223.55% | -8399.31% | -2726.06% | -2875.69% | -5653.59% | -3686.33% |
| Operating Income | $-73.52M | $-14.68M | $68.70M | $-49.26M | $-54.02M | $-46.29M | $-44.91M | $1.66M | $-27.24M | $-42.99M | $-43.75M | $-49.98M | $-42.86M | $-42.18M | $-39.31M | $-37.89M | $-37.51M | $-35.88M | $-30.25M | $-29.76M |
| Operating Income Ratio | -2281.78% | -35.89% | 53.58% | -867.58% | -23182.73% | -632.44% | -875.40% | 3.48% | -247.03% | -613.53% | -790.03% | -1398.07% | -3024.98% | -3506.32% | -1270.18% | -8730.18% | -2497.54% | -3007.12% | -6026.49% | -3911.17% |
| Total Other Income Expenses Net | $997.00K | $-2.11M | $-957.14K | $1.28M | $1.28M | $1.72M | $24.20M | $5.00K | $-3.31M | $1.97M | $-298.00K | $350.00K | $4.21M | $-12.00K | $320.00K | $424.00K | $952.00K | $458.00K | $398.00K | $1.67M |
| Income Before Tax | $-72.52M | $-16.79M | $67.74M | $-47.98M | $-52.72M | $-44.91M | $-20.71M | $1.66M | $-28.26M | $-41.02M | $-44.05M | $-49.63M | $-38.65M | $-42.19M | $-38.99M | $-37.47M | $-36.56M | $-35.42M | $-29.86M | $-28.10M |
| Income Before Tax Ratio | -2250.84% | -41.04% | 52.83% | -844.96% | -22627.32% | -613.66% | -403.68% | 3.49% | -256.22% | -585.44% | -795.41% | -1388.28% | -2727.52% | -3507.32% | -1259.84% | -8632.49% | -2434.15% | -2968.73% | -5947.21% | -3692.12% |
| Income Tax Expense | $1.69M | $831.00K | $-1.86M | $-526.00K | $-4.39M | $-687.00K | $680.00K | $625.00K | $994.00K | $399.00K | $470.00K | $634.00K | $210.00K | $208.00K | $76.00K | $298.00K | $52.00K | $15.00K | $25.00K | $70.00K |
| Net Income | $-74.22M | $-17.62M | $69.52M | $-48.50M | $-48.33M | $-45.60M | $-21.39M | $1.04M | $-29.25M | $-41.42M | $-44.52M | $-50.27M | $-38.86M | $-42.40M | $-39.07M | $-37.76M | $-36.61M | $-35.43M | $-29.88M | $-28.17M |
| Net Income Ratio | -2303.38% | -43.07% | 54.22% | -854.23% | -20743.33% | -623.05% | -416.94% | 2.18% | -265.23% | -591.14% | -803.90% | -1406.01% | -2742.34% | -3524.61% | -1262.29% | -8701.15% | -2437.62% | -2969.99% | -5952.19% | -3701.31% |
| EPS | $-0.29 | $-0.07 | $0.27 | $-0.20 | $-0.21 | $-0.20 | $-0.12 | $0.01 | $-0.18 | $-0.25 | $-0.28 | $-0.32 | $-0.25 | $-0.27 | $-0.25 | $-0.24 | $-0.24 | $-0.23 | $-0.22 | $-0.23 |
| EPS Diluted | $-0.29 | $-0.07 | $0.27 | $-0.20 | $-0.21 | $-0.20 | $-0.12 | $0.01 | $-0.18 | $-0.25 | $-0.28 | $-0.32 | $-0.25 | $-0.27 | $-0.25 | $-0.24 | $-0.24 | $-0.23 | $-0.22 | $-0.23 |
| Weighted Average Shares Outstanding | 252.30M | 255.77M | 255.59M | 241.87M | 227.11M | 226.31M | 184.69M | 165.22M | 164.12M | 163.47M | 160.47M | 156.67M | 156.22M | 156.10M | 155.70M | 155.18M | 154.78M | 154.67M | 137.12M | 123.29M |
| Weighted Average Shares Outstanding Diluted | 252.30M | 255.77M | 259.86M | 241.87M | 227.11M | 226.31M | 184.69M | 166.71M | 164.12M | 163.47M | 160.47M | 156.67M | 156.22M | 156.10M | 155.70M | 155.18M | 154.78M | 154.67M | 137.12M | 123.29M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $91.14M | $143.99M | $108.03M | $149.95M | $56.88M |
| Short Term Investments | $60.47M | $2.95M | $96.57M | $219.63M | $311.33M |
| Cash and Short Term Investments | $151.60M | $146.94M | $204.60M | $369.58M | $368.22M |
| Net Receivables | $1.45M | $46.92M | $7.43M | $752.00K | $139.00K |
| Inventory | $7.32M | $- | $1.28M | $746.00K | $2.09M |
| Other Current Assets | $27.79M | $13.70M | $51.52M | $54.17M | $34.02M |
| Total Current Assets | $188.17M | $207.55M | $255.37M | $415.46M | $398.15M |
| Property Plant Equipment Net | $51.22M | $71.71M | $71.53M | $51.37M | $46.66M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $3.88M | $330.00K | $442.00K | $1.00M | $1.73M |
| Goodwill and Intangible Assets | $3.88M | $330.00K | $442.00K | $1.00M | $1.73M |
| Long Term Investments | $- | $- | $1.57M | $1.72M | $4.60M |
| Tax Assets | $- | $- | $-1.57M | $-1.72M | $-4.60M |
| Other Non-Current Assets | $2.70M | $3.03M | $1.57M | $1.72M | $4.60M |
| Total Non-Current Assets | $57.79M | $75.06M | $73.55M | $54.09M | $52.99M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $245.96M | $282.62M | $328.92M | $469.55M | $451.14M |
| Account Payables | $8.69M | $8.13M | $4.75M | $8.11M | $6.39M |
| Short Term Debt | $4.71M | $5.38M | $5.46M | $4.64M | $5.55M |
| Tax Payables | $- | $1.40M | $- | $- | $- |
| Deferred Revenue | $12.30M | $28.97M | $23.52M | $22.20M | $2.83M |
| Other Current Liabilities | $38.83M | $28.91M | $30.77M | $27.59M | $24.31M |
| Total Current Liabilities | $64.53M | $72.79M | $64.50M | $62.54M | $39.07M |
| Long Term Debt | $19.26M | $19.85M | $40.70M | $46.30M | $41.88M |
| Deferred Revenue Non-Current | $- | $149.06M | $160.89M | $177.22M | $49.26M |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $150.32M | $1.40M | $-19.05M | $-22.48M | $-20.29M |
| Total Non-Current Liabilities | $169.59M | $170.31M | $182.54M | $201.04M | $70.84M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $234.11M | $243.10M | $247.04M | $263.58M | $109.92M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.08M | $1.86M | $1.40M | $1.34M | $1.32M |
| Retained Earnings | $-1.09B | $-1.02B | $-909.30M | $-743.85M | $-585.76M |
| Accumulated Other Comprehensive Income Loss | $-1.90M | $-3.75M | $-875.00K | $-11.14M | $-10.05M |
| Other Total Stockholders Equity | $1.11B | $1.06B | $990.66M | $959.61M | $935.71M |
| Total Stockholders Equity | $11.85M | $39.51M | $81.88M | $205.96M | $341.23M |
| Total Equity | $11.85M | $39.51M | $81.88M | $205.96M | $341.23M |
| Total Liabilities and Stockholders Equity | $245.96M | $282.62M | $328.92M | $469.55M | $451.14M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $245.96M | $282.62M | $328.92M | $469.55M | $451.14M |
| Total Investments | $60.47M | $2.95M | $96.57M | $219.63M | $311.33M |
| Total Debt | $23.97M | $25.23M | $23.08M | $25.47M | $23.71M |
| Net Debt | $-67.17M | $-118.76M | $-84.96M | $-124.48M | $-33.17M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $91.14M | $116.74M | $211.81M | $140.67M | $143.99M | $90.06M | $76.97M | $119.87M | $108.03M | $79.00M | $97.81M | $89.54M | $149.95M | $42.92M | $50.45M | $32.43M | $56.88M | $78.47M | $122.36M | $86.43M |
| Short Term Investments | $60.47M | $69.35M | $2.98M | $2.98M | $2.95M | $71.67M | $127.74M | $45.69M | $96.57M | $120.67M | $160.28M | $214.68M | $219.63M | $197.20M | $234.92M | $285.51M | $311.33M | $321.44M | $296.63M | $110.00M |
| Cash and Short Term Investments | $151.60M | $186.09M | $214.79M | $143.65M | $146.94M | $161.73M | $204.71M | $165.55M | $204.60M | $199.67M | $258.09M | $304.22M | $369.58M | $240.12M | $285.37M | $317.94M | $368.22M | $399.91M | $418.99M | $196.43M |
| Net Receivables | $15.98M | $38.61M | $23.77M | $28.89M | $46.92M | $789.00K | $40.92M | $1.72M | $38.09M | $53.53M | $49.42M | $42.89M | $752.00K | $45.09M | $39.91M | $31.14M | $20.72M | $13.92M | $26.75M | $23.00M |
| Inventory | $7.32M | $1.87M | $- | $1 | $1.33M | $1.29M | $1.33M | $1.31M | $1.28M | $8.05M | $1.33M | $10.08M | $746.00K | $1.28M | $1.59M | $1.58M | $2.09M | $2.49M | $1.52M | $952.00K |
| Other Current Assets | $13.26M | $17.64M | $15.22M | $14.36M | $13.70M | $67.53M | $16.14M | $51.96M | $12.68M | $10.94M | $13.65M | $12.36M | $54.17M | $13.96M | $10.47M | $8.63M | $9.21M | $10.42M | $10.83M | $7.38M |
| Total Current Assets | $188.17M | $244.21M | $253.77M | $186.90M | $207.55M | $219.37M | $261.77M | $213.75M | $255.37M | $264.14M | $321.17M | $359.46M | $415.46M | $300.45M | $337.34M | $359.29M | $398.15M | $426.73M | $458.09M | $227.76M |
| Property Plant Equipment Net | $51.22M | $65.29M | $64.07M | $67.72M | $71.71M | $73.87M | $77.52M | $72.31M | $71.53M | $65.78M | $64.78M | $57.83M | $51.37M | $50.17M | $46.44M | $46.06M | $46.66M | $45.72M | $45.91M | $48.17M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $3.88M | $4.28M | $996.00K | $524.00K | $330.00K | $384.00K | $463.00K | $443.00K | $442.00K | $568.00K | $612.00K | $788.00K | $1.00M | $1.19M | $1.38M | $1.62M | $1.73M | $1.97M | $2.13M | $2.37M |
| Goodwill and Intangible Assets | $3.88M | $4.28M | $996.00K | $524.00K | $330.00K | $384.00K | $463.00K | $443.00K | $442.00K | $568.00K | $612.00K | $788.00K | $1.00M | $1.19M | $1.38M | $1.62M | $1.73M | $1.97M | $2.13M | $2.37M |
| Long Term Investments | $- | $- | $2.87M | $2.86M | $3.03M | $3.01M | $3.23M | $1.58M | $1.57M | $1.71M | $1.71M | $1.72M | $1.72M | $1.72M | $4.63M | $4.60M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $-2.87M | $-2.86M | $-3.03M | $-3.01M | $-3.23M | $-1.58M | $-1.57M | $-1.71M | $-1.71M | $-1.72M | $-1.72M | $-1.72M | $-4.63M | $-4.60M | $- | $- | $- | $- |
| Other Non-Current Assets | $2.70M | $3.65M | $-1 | $2.86M | $3.03M | $3.01M | $3.23M | $1.58M | $1.57M | $1.71M | $1.71M | $1.72M | $1.72M | $1.72M | $4.63M | $4.60M | $4.60M | $4.60M | $6.07M | $6.94M |
| Total Non-Current Assets | $57.79M | $73.22M | $67.93M | $71.11M | $75.06M | $77.27M | $81.21M | $74.33M | $73.55M | $68.06M | $67.11M | $60.34M | $54.09M | $53.08M | $52.45M | $52.29M | $52.99M | $52.29M | $54.11M | $57.48M |
| Other Assets | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $245.96M | $317.44M | $321.70M | $258.01M | $282.62M | $296.64M | $342.98M | $288.08M | $328.92M | $332.20M | $388.27M | $419.80M | $469.55M | $353.53M | $389.79M | $411.58M | $451.14M | $479.02M | $512.20M | $285.24M |
| Account Payables | $8.69M | $9.07M | $7.51M | $6.59M | $8.13M | $13.92M | $14.71M | $5.19M | $4.75M | $6.91M | $15.99M | $7.02M | $8.11M | $4.78M | $6.98M | $4.12M | $6.39M | $4.03M | $8.77M | $7.07M |
| Short Term Debt | $4.71M | $4.17M | $10.59M | $5.25M | $10.77M | $10.16M | $4.75M | $2.84M | $2.73M | $4.95M | $5.11M | $2.73M | $4.64M | $4.53M | $5.84M | $2.85M | $2.77M | $5.24M | $4.99M | $5.18M |
| Tax Payables | $- | $- | $- | $- | $1.40M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $12.30M | $18.71M | $38.42M | $31.52M | $28.97M | $29.31M | $31.42M | $22.30M | $23.52M | $20.62M | $22.47M | $24.77M | $22.20M | $6.10M | $4.91M | $2.08M | $2.83M | $3.63M | $3.46M | $1.66M |
| Other Current Liabilities | $38.83M | $31.50M | $25.56M | $23.05M | $23.52M | $21.75M | $25.24M | $33.30M | $33.50M | $33.60M | $30.06M | $31.63M | $27.59M | $25.72M | $23.68M | $22.26M | $27.08M | $22.00M | $21.34M | $15.91M |
| Total Current Liabilities | $64.53M | $63.46M | $82.07M | $66.41M | $72.79M | $75.15M | $76.12M | $63.63M | $64.50M | $66.08M | $73.63M | $66.15M | $62.54M | $41.14M | $41.42M | $31.31M | $39.07M | $34.90M | $38.56M | $29.82M |
| Long Term Debt | $69.50M | $70.32M | $34.20M | $18.44M | $39.70M | $41.04M | $21.59M | $39.98M | $20.35M | $39.85M | $43.27M | $46.44M | $46.30M | $47.41M | $39.45M | $39.79M | $20.94M | $42.18M | $41.63M | $43.66M |
| Deferred Revenue Non-Current | $95.81M | $- | $99.86M | $147.37M | $149.06M | $111.49M | $117.26M | $119.25M | $160.89M | $132.23M | $150.44M | $166.61M | $177.22M | $47.04M | $50.05M | $50.56M | $49.26M | $46.21M | $44.65M | $46.97M |
| Deferred Tax Liabilities Non-Current | $- | $- | $7.85M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $4.27M | $103.67M | $9.29M | $1.42M | $-18.45M | $-19.16M | $1.36M | $-18.66M | $1.30M | $-19.30M | $-20.99M | $-22.55M | $-22.48M | $-23.04M | $-19.06M | $-19.24M | $644.00K | $-20.48M | $-20.22M | $-21.24M |
| Total Non-Current Liabilities | $169.59M | $173.99M | $143.35M | $167.22M | $170.31M | $133.36M | $140.21M | $140.57M | $182.54M | $152.78M | $172.72M | $190.50M | $201.04M | $71.41M | $70.44M | $71.12M | $70.84M | $67.92M | $66.06M | $69.39M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $234.11M | $237.45M | $225.43M | $233.63M | $243.10M | $208.51M | $216.33M | $204.21M | $247.04M | $218.87M | $246.35M | $256.65M | $263.58M | $112.55M | $111.85M | $102.42M | $109.92M | $102.82M | $104.62M | $99.20M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $2.08M | $2.08M | $2.08M | $2.08M | $1.86M | $1.86M | $1.85M | $1.41M | $1.40M | $1.39M | $1.39M | $1.34M | $1.34M | $1.34M | $1.34M | $1.33M | $1.32M | $1.32M | $1.32M | $1.14M |
| Retained Earnings | $-1.09B | $-1.02B | $-1.00B | $-1.07B | $-1.02B | $-975.26M | $-929.65M | $-908.27M | $-909.30M | $-880.05M | $-838.63M | $-794.11M | $-743.85M | $-704.99M | $-662.59M | $-623.52M | $-585.76M | $-549.14M | $-513.71M | $-483.83M |
| Accumulated Other Comprehensive Income Loss | $-1.90M | $-5.14M | $-3.41M | $-2.72M | $-3.75M | $102.00K | $-3.09M | $-1.78M | $-875.00K | $6.68M | $-1.04M | $-9.31M | $-11.14M | $-10.10M | $-10.38M | $-10.22M | $-10.05M | $-8.49M | $-8.80M | $-9.59M |
| Other Total Stockholders Equity | $1.11B | $1.10B | $1.10B | $1.10B | $1.06B | $1.06B | $1.06B | $992.52M | $990.66M | $985.31M | $980.20M | $965.23M | $959.61M | $954.73M | $949.58M | $941.57M | $935.71M | $932.52M | $928.78M | $678.32M |
| Total Stockholders Equity | $11.85M | $79.99M | $96.27M | $24.38M | $39.51M | $88.13M | $126.65M | $83.88M | $81.88M | $113.34M | $141.92M | $163.15M | $205.96M | $240.98M | $277.94M | $309.16M | $341.23M | $376.21M | $407.58M | $186.04M |
| Total Equity | $11.85M | $79.99M | $96.27M | $24.38M | $39.51M | $88.13M | $126.65M | $83.88M | $81.88M | $113.34M | $141.92M | $163.15M | $205.96M | $240.98M | $277.94M | $309.16M | $341.23M | $376.21M | $407.58M | $186.04M |
| Total Liabilities and Stockholders Equity | $245.96M | $317.44M | $321.70M | $258.01M | $282.62M | $296.64M | $342.98M | $288.08M | $328.92M | $332.20M | $388.27M | $419.80M | $469.55M | $353.53M | $389.79M | $411.58M | $451.14M | $479.02M | $512.20M | $285.24M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $245.96M | $317.44M | $321.70M | $258.01M | $282.62M | $296.64M | $342.98M | $288.08M | $328.92M | $332.20M | $388.27M | $419.80M | $469.55M | $353.53M | $389.79M | $411.58M | $451.14M | $479.02M | $512.20M | $285.24M |
| Total Investments | $60.47M | $69.35M | $5.84M | $5.84M | $5.97M | $71.67M | $127.74M | $45.69M | $96.57M | $120.67M | $160.28M | $214.68M | $219.63M | $197.20M | $234.92M | $285.51M | $311.33M | $321.44M | $296.63M | $110.00M |
| Total Debt | $74.21M | $74.50M | $47.35M | $23.69M | $25.23M | $25.60M | $26.34M | $22.83M | $23.08M | $22.40M | $24.19M | $25.95M | $25.47M | $25.97M | $22.64M | $22.74M | $23.71M | $23.71M | $23.31M | $24.42M |
| Net Debt | $-16.93M | $-42.25M | $-164.46M | $-116.98M | $-118.76M | $-64.46M | $-50.63M | $-97.03M | $-84.96M | $-56.60M | $-73.62M | $-63.58M | $-124.48M | $-16.95M | $-27.81M | $-9.69M | $-33.17M | $-54.76M | $-99.05M | $-62.01M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-70.81M | $-113.87M | $-165.46M | $-158.09M | $-130.09M |
| Depreciation and Amortization | $10.81M | $9.45M | $6.08M | $6.57M | $7.59M |
| Deferred Income Tax | $- | $- | $- | $5.82M | $2.50M |
| Stock Based Compensation | $12.05M | $11.77M | $18.24M | $20.63M | $10.41M |
| Change in Working Capital | $-36.98M | $-25.05M | $-1.53M | $134.63M | $56.05M |
| Accounts Receivables | $- | $- | $-9.81M | $-19.36M | $1.76M |
| Inventory | $-7.36M | $- | $5.40M | $15.15M | $-5.66M |
| Accounts Payables | $- | $- | $4.41M | $4.21M | $3.90M |
| Other Working Capital | $-29.62M | $-25.05M | $-1.53M | $134.63M | $56.05M |
| Other Non Cash Items | $11.72M | $-23.19M | $903.00K | $1.17M | $-55.00K |
| Net Cash Provided by Operating Activities | $-73.21M | $-140.88M | $-141.77M | $10.73M | $-53.59M |
| Investments in Property Plant and Equipment | $- | $-4.68M | $-29.74M | $-8.78M | $-2.91M |
| Acquisitions Net | $- | $45.26M | $77.86M | $207.00K | $565.00K |
| Purchases of Investments | $- | $-75.95M | $-48.12M | $-139.76M | $-381.04M |
| Sales Maturities of Investments | $44.06M | $210.98M | $166.99M | $224.34M | $105.02M |
| Other Investing Activities | $-103.01M | $925.00K | $-77.86M | $-207.00K | $-565.00K |
| Net Cash Used for Investing Activities | $-58.95M | $176.54M | $89.14M | $75.80M | $-278.92M |
| Debt Repayment | $49.50M | $- | $- | $- | $- |
| Common Stock Issued | $29.17M | $624.00K | $12.82M | $2.53M | $334.39M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $77.00K | $256.00K | $50.00K | $759.00K | $5.66M |
| Net Cash Used Provided by Financing Activities | $78.75M | $880.00K | $12.87M | $3.29M | $340.05M |
| Effect of Forex Changes on Cash | $-402.00K | $877.00K | $-2.30M | $365.00K | $-960.00K |
| Net Change in Cash | $-53.81M | $37.41M | $-42.06M | $90.18M | $6.58M |
| Cash at End of Period | $93.21M | $147.02M | $109.60M | $151.67M | $61.48M |
| Cash at Beginning of Period | $147.02M | $109.60M | $151.67M | $61.48M | $54.91M |
| Operating Cash Flow | $-73.21M | $-140.88M | $-141.77M | $10.73M | $-53.59M |
| Capital Expenditure | $- | $-4.88M | $-29.74M | $-8.78M | $-2.91M |
| Free Cash Flow | $-73.21M | $-145.76M | $-171.51M | $1.95M | $-56.50M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-74.22M | $-17.62M | $69.52M | $-48.48M | $-48.33M | $-45.60M | $-21.39M | $1.04M | $-29.25M | $-41.42M | $-44.52M | $-50.27M | $-38.86M | $-42.40M | $-39.07M | $-37.76M | $-36.61M | $-35.43M | $-29.88M | $-28.17M |
| Depreciation and Amortization | $2.83M | $2.82M | $2.74M | $2.83M | $2.87M | $2.89M | $2.23M | $1.84M | $1.44M | $1.49M | $1.55M | $1.59M | $2.23M | $1.45M | $1.44M | $1.44M | $1.73M | $1.82M | $2.16M | $1.89M |
| Deferred Income Tax | $- | $- | $- | $- | $-10.71M | $-630.00K | $-931.00K | $- | $- | $- | $- | $- | $1.94M | $1.26M | $-131.00K | $2.75M | $3.60M | $902.00K | $-259.00K | $-1.75M |
| Stock Based Compensation | $2.84M | $3.05M | $994.00K | $3.10M | $3.08M | $3.18M | $3.84M | $1.68M | $3.95M | $3.66M | $5.04M | $5.59M | $4.83M | $5.02M | $5.45M | $5.33M | $3.06M | $3.28M | $2.62M | $1.45M |
| Change in Working Capital | $25.55M | $-45.53M | $-27.35M | $10.35M | $28.42M | $-4.70M | $-5.88M | $-42.65M | $25.43M | $-10.21M | $-4.47M | $-12.29M | $164.86M | $-11.37M | $746.00K | $-19.59M | $1.88M | $11.01M | $-129.00K | $43.28M |
| Accounts Receivables | $24.34M | $- | $- | $15.61M | $-583.87K | $-2.70M | $-1.73M | $3.72M | $19.66M | $-6.71M | $-12.14M | $-10.70M | $12.53M | $-10.41M | $-10.32M | $-11.15M | $-1.60M | $13.45M | $-6.91M | $-3.19M |
| Inventory | $-5.49M | $- | $- | $- | $-1 | $1.67M | $10.61M | $-3.74M | $-9.03M | $4.49M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $-7.65M | $-1.30M | $1.03M | $-8.88M | $21.19K | $-10.64M | $2.22M | $11.86M | $958.49K | $4.32M | $-772.74K | $9.26M | $-8.60M | $- | $- | $- | $- |
| Other Working Capital | $6.69M | $-45.53M | $-27.35M | $2.39M | $30.30M | $-4.70M | $-5.88M | $-42.65M | $25.43M | $-10.21M | $-4.26M | $-12.29M | $164.86M | $-11.37M | $746.00K | $-19.59M | $1.88M | $11.01M | $-129.00K | $43.28M |
| Other Non Cash Items | $8.79M | $2.82M | $1.48M | $1.05M | $10.01M | $-304.00K | $-21.63M | $809.00K | $474.00K | $-1.68M | $365.00K | $975.00K | $-1.07M | $838.00K | $102.00K | $1.30M | $-2.87M | $2.10M | $573.00K | $145.00K |
| Net Cash Provided by Operating Activities | $-34.20M | $-54.45M | $47.39M | $-31.93M | $-14.66M | $-45.16M | $-43.76M | $-37.28M | $2.04M | $-48.16M | $-41.25M | $-54.40M | $133.93M | $-45.20M | $-31.46M | $-46.54M | $-29.22M | $-16.32M | $-24.91M | $16.86M |
| Investments in Property Plant and Equipment | $-219.00K | $-143.00K | $-754.55K | $-357.80K | $-828.02K | $-289.00K | $-1.24M | $-2.52M | $-3.43M | $-10.24M | $-8.96M | $-7.11M | $-4.04M | $-1.67M | $-1.78M | $-1.28M | $-1.24M | $-803.00K | $-523.00K | $-344.00K |
| Acquisitions Net | $- | $- | $- | $- | $-24.45K | $-86.56K | $26.00K | $- | $-24.37M | $-39.04M | $- | $49.31M | $26.00K | $38.00K | $10.00K | $133.00K | $69.00K | $89.00K | $255.00K | $152.00K |
| Purchases of Investments | $-34.72M | $-65.70M | $- | $- | $-2.90M | $-5.91M | $-67.12M | $- | $-5.92M | $178.49K | $14.19K | $-42.20M | $-58.40M | $595.00K | $-20.36M | $-61.60M | $-17.26M | $-65.76M | $-200.05M | $-97.97M |
| Sales Maturities of Investments | $44.06M | $- | $- | $- | $71.94M | $63.12M | $25.26M | $50.86M | $30.30M | $39.09M | $53.07M | $44.54M | $33.95M | $35.93M | $69.82M | $84.65M | $26.11M | $38.98M | $13.57M | $26.36M |
| Other Investing Activities | $-954.00K | $-174.00K | $11.00K | $-358.00K | $211.32K | $462.56K | $45.77M | $50.69M | $24.37M | $38.86M | $53.07M | $-49.31M | $-26.00K | $-38.00K | $-10.00K | $-133.00K | $-69.00K | $-89.00K | $-255.00K | $-152.00K |
| Net Cash Used for Investing Activities | $8.17M | $-66.02M | $-743.55K | $-357.80K | $68.40M | $57.31M | $2.69M | $48.34M | $20.95M | $28.85M | $44.11M | $-4.78M | $-28.49M | $34.85M | $47.68M | $21.76M | $7.61M | $-27.58M | $-187.00M | $-71.95M |
| Debt Repayment | $- | $25.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $1.00K | $- | $10.00K | $29.16M | $1.00K | $435.00K | $13.55K | $188.00K | $1.40M | $1.45M | $9.98M | $34.80K | $44.15K | $10.00K | $2.52M | $534.00K | $-334.39M | $- | $243.84M | $90.55M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $1.00K | $24.50M | $74.00K | $73.00K | $161.00K | $14.00K | $8.00K | $8.00K | $6.00K | $1.00K | $35.00K | $52.00K | $129.00K | $44.00K | $534.00K | $122.00K | $466.00K | $4.18M | $894.00K |
| Net Cash Used Provided by Financing Activities | $1.00K | $25.00M | $24.51M | $29.22M | $73.85K | $596.00K | $14.00K | $196.00K | $1.40M | $1.45M | $9.98M | $35.00K | $52.00K | $139.00K | $2.56M | $534.00K | $122.00K | $466.00K | $248.02M | $91.44M |
| Effect of Forex Changes on Cash | $-180.00K | $214.00K | $-20.00K | $-416.00K | $350.00K | $129.00K | $-190.00K | $588.00K | $4.49M | $-955.00K | $-4.57M | $-1.27M | $1.54M | $-240.00K | $-733.00K | $-204.00K | $63.00K | $-345.00K | $-176.00K | $-502.00K |
| Net Change in Cash | $-26.22M | $-95.25M | $71.14M | $-3.32M | $53.93M | $12.87M | $-41.24M | $11.84M | $28.89M | $-18.81M | $8.27M | $-60.41M | $107.03M | $-10.45M | $18.05M | $-24.45M | $-21.42M | $-43.78M | $35.92M | $35.85M |
| Cash at End of Period | $93.21M | $119.42M | $211.81M | $140.67M | $143.99M | $93.07M | $80.20M | $121.44M | $109.60M | $80.71M | $99.52M | $91.25M | $151.67M | $44.63M | $55.09M | $37.04M | $61.48M | $82.91M | $126.68M | $90.76M |
| Cash at Beginning of Period | $119.42M | $214.68M | $140.67M | $143.99M | $90.06M | $80.20M | $121.44M | $109.60M | $80.71M | $99.52M | $91.25M | $151.67M | $44.63M | $55.09M | $37.04M | $61.48M | $82.91M | $126.68M | $90.76M | $54.91M |
| Operating Cash Flow | $-34.20M | $-54.45M | $47.39M | $-31.93M | $-14.66M | $-45.16M | $-43.76M | $-37.28M | $2.04M | $-48.16M | $-41.25M | $-54.40M | $133.93M | $-45.20M | $-31.46M | $-46.54M | $-29.22M | $-16.32M | $-24.91M | $16.86M |
| Capital Expenditure | $-1.17M | $-435.00K | $-754.55K | $-357.80K | $-828.02K | $-289.00K | $-1.24M | $-2.52M | $-3.43M | $-10.24M | $-8.96M | $-7.11M | $-4.04M | $-1.67M | $-1.78M | $-1.28M | $-1.24M | $-803.00K | $-523.00K | $-344.00K |
| Free Cash Flow | $-35.38M | $-54.89M | $46.63M | $-32.29M | $-15.49M | $-45.45M | $-45.00M | $-39.80M | $-1.39M | $-58.40M | $-50.21M | $-61.52M | $129.89M | $-46.87M | $-33.24M | $-47.83M | $-30.45M | $-17.12M | $-25.44M | $16.51M |
Adaptimmune Therapeutics plc Dividends
Explore Adaptimmune Therapeutics plc's dividend history, including dividend yield, payout ratio, and historical payments.
Adaptimmune Therapeutics plc News
Read the latest news about Adaptimmune Therapeutics plc, including recent articles, headlines, and updates.
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q4 2024 Earnings Conference Call March 20, 2025 8:00 AM ET Company Participants Juli Miller - IR Adrian Rawcliffe - CEO Cintia Piccina - Chief Commercial Officer Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development John Lunger - VP, Manufacturing and Supply Chain Conference Call Participants Jonathan Chang - Leerink Partners Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho George Farmer - Scotiabank Arthur He - H.C. Wainwright Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello, and welcome to the Adaptimmune's Q4 and Full Year 2024 Business Update Conference Call.
Adaptimmune Provides Q4 and Full Year 2024 Business Update
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals achieved Lete-cel on track to initiate rolling BLA submission late 2025; approval anticipated 2026 Corporate restructure completed in February 2025 and implementing additional cost reduction for PRAME and CD70 programs At the end of 2024, Adaptimmune had Total Liquidity 1 of $152 million Evaluating all strategic options to maximize shareholder value Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today provided a Q4 and Full Year 2024 business update. Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise.
Adaptimmune to Report Full Year and Q4 2024 Financial and Business Updates on Thursday, March 20, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - March 12, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the fourth quarter and full year ended December 31, 2024, before the US markets open on Thursday, March 20, 2025. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune to Participate in the Guggenheim Securities SMID Cap Biotech Conference February 6, 2025
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 30, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in the Guggenheim Securities SMID Cap Biotech Conference this February. Guggenheim Securities SMID Cap Biotech Conference, New York, NY Fireside chat with Adrian Rawcliffe, CEO: February 6 at 3:00 p.m.
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
The Company will present at the Annual J.P. Morgan Healthcare Conference, providing business updates on its sarcoma franchise and other cell therapy pipeline assets Adaptimmune Allo-T program to be featured at the Biotech ShowCase (TM) and the Wuxi Global Forum 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - January 13, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that letetresgene autoleucel (lete-cel), has been granted breakthrough therapy designation by the U.S. FDA for the treatment of patients with unresectable or metastatic myxoid/round cell liposarcoma (MRCLS) who have received prior anthracycline-based chemotherapy, are positive for HLA-A*02:01, HLA-A*02:05, or HLA-A*02:06, and whose tumor expresses the NY-ESO-1 antigen.
Adaptimmune Announces Changes to its Executive Leadership Team Based in The UK
Helen Tayton-Martin, Ph.D., M.B.A, Adaptimmune Co-Founder and Chief Business & Strategy Officer, will step down from the Company March 31, 2025 Gavin Wood, Chief Financial Officer, will step down from the Company May 31, 2025 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 19, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that two of its executive leadership team members based in the UK will leave the Company next year.
First Patient Treated with Adaptimmune's TECELRA(R) (afamitresgene autoleucel)
Dosing marks a milestone for first engineered cell therapy approved in the U.S. for a solid tumor cancer, synovial sarcoma Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - December 2, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that the first patient has been treated with TECELRA® (afamitresgene autoleucel). TECELRA is the first engineered cell therapy for a solid tumor cancer approved in the U.S., and the first new therapy option in more than a decade for synovial sarcoma, a rare, soft tissue cancer that most commonly impacts young adults.
Adaptimmune Therapeutics plc (ADAP) Q3 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Dan Od-Cohen - IR Adrian Rawcliffe - CEO Gavin Wood - CFO Dennis Williams - SVP, Late Stage Development Conference Call Participants Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Paul Jeng - Guggenheim Yen-Der Li - Leerink Partners Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright George Farmer - Scotiabank Michael Kim - Zacks Small Cap Research Peter Lawson - Barclays Operator Hello and welcome to the Adaptimmune Therapeutics Third Quarter 2024 Results Conference Call.
Adaptimmune Reports Q3 2024 Financial and Business Updates
Tecelra® launch on track with 9 Authorized Treatment Centers available to initiate patient treatment journey, and the first patient apheresed in Q3; expect first commercial revenues in Q4 and the number of treated patients to accelerate throughout 2025 Lete-cel IGNYTE-ESO pivotal trial primary analysis reports 42% overall response rate in synovial sarcoma and myxoid/round cell liposarcoma (MRCLS); full data at CTOS conference on November 16 Company restructuring to prioritize commercial sarcoma franchise and R&D programs with highest potential return on invested capital and transformational benefit to patients Planned 33% reduction in headcount in Q1, 2025 as part of approximately $300 million in aggregate cost savings over the next four years enables company to target an operating breakeven during 2027 At the end of Q3, Adaptimmune had Total Liquidity1 of $186.1 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the third quarter ended September 30, 2024. The Company will host a live webcast at 4:30 p.m.
Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial
42% of people with advanced or metastatic synovial sarcoma or MRCLS had clinical responses with lete-cel Results include six complete responses (6/64); twenty-one partial responses (21/64) Data to be presented at Connective Tissue Oncology Society 2024 Annual Meeting Company plans to initiate a rolling BLA submission for lete-cel for the treatment of advanced or metastatic synovial sarcoma and MRCLS by end of 2025 Company to host virtual KOL event Monday, November 18, 2024; 2:30 PM EST featuring Dr. Sandra D'Angelo, M.D. (Memorial Sloan Kettering Cancer Center) - register here Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 13, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced data from the primary analysis of its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in people with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS) who received previous anthracycline-based therapy.
Adaptimmune to Participate in Scientific and Medical Conferences this November and December
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 5, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced presence and presentations at key scientific and medical conferences in November and December. Society for Immunotherapy of Cancer (SITC) 39 th annual meeting, November 6-10, Houston, TX Podium presentation: "Delivering on the Promise of Cell Therapies for Solid Tumors: T-cell Therapy for Synovial Sarcoma" / Jo Brewer, PhD, Chief Scientific Officer, Adaptimmune.
Adaptimmune to Report Q3 2024 Financial and Business Updates on Wednesday, November 13, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 31, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the third quarter ended September 30, 2024, after the US markets close on Wednesday, November 13, 2024. Following the announcement, the Company will host a live webcast at 4:30 p.m.
Adaptimmune to Participate in Two Bank Conferences this September
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 28, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced that management will participate in two investment bank conferences this September. Wells Fargo Healthcare Conference, Boston, MA Fireside chat: Wednesday September 4, 2024, at 4:30 PM EDT.
Adaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2024 Earnings Conference Call August 12, 2024 8:00 AM ET Company Participants Dan Od-Cohen - Investor Relations Adrian Rawcliffe - Chief Executive Officer Cintia Piccina - Chief Commercial Officer Joanna Brewer - Chief Scientific Officer Dennis Williams - Senior Vice President, Late Stage Development John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Marc Frahm - TD Cowen Matthew Cowper - Leerink Partners Paul Jeng - Guggenheim Securities Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities George Farmer - Scotiabank Arthur He - H.C. Wainwright Kuan-Hung Lin - Wells Fargo Michael Kim - Zacks Small-Cap Research Alexandre Bouilloux - Barclays Operator Good day and welcome to the Adaptimmune Second Quarter 2024 Conference Call.
Adaptimmune Reports Q2 2024 Financial and Business Updates
Adaptimmune received U.S. FDA accelerated approval of Tecelra® (afami-cel), the first approved engineered cell therapy for a solid tumor Patients can begin treatment journey; biomarker testing available; Adaptimmune systems ready to receive orders At the end of Q2, Adaptimmune had Total Liquidity[1] of $214.8 million Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 12, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the second quarter ended June 30, 2024. The Company will host a live webcast at 8:00 a.m.
Adaptimmune to Report Q2 2024 Financial and Business Updates on Monday, August 12, 2024
Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - August 5, 2024) - Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the second quarter ended June 30, 2024, before the US markets open on Monday, August 12, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune Receives U.S. FDA Accelerated Approval of TECELRA® (afamitresgene autoleucel), the First Approved Engineered Cell Therapy for a Solid Tumor
PHILADELPHIA & OXFORD, England--(BUSINESS WIRE)--Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, today announced U.S. Food and Drug Administration (FDA) accelerated approval of TECELRA® (afamitresgene autoleucel) for the treatment of adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses.
Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Adaptimmune Therapeutics is focused on late-stage development of cell therapy for cancer, particularly in sarcoma management. Pipeline updates include progress on afami-cel for soft tissue sarcomas and lete-cel for synovial sarcoma. Financially, ADAP has a cash runway of around 3 quarters, with potential resources from collaborations and agreements extending it further.
Adaptimmune to Present Data from Planned Interim Analysis of Pivotal IGNYTE-ESO Trial with Lete-cel at ASCO; Data Continue to Support further Development of Sarcoma Franchise
Overall response rate of 40% consistent across sarcoma indications; median duration of response ~11 months with patients still in response at time of analysis Interim analysis data reinforces the potential of lete-cel to bolster Adaptimmune's sarcoma franchise by expanding addressable sarcoma patient population Full results from the pivotal IGNYTE-ESO trial are expected in late 2024 Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - June 3, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company working to redefine the treatment of solid tumor cancers with cell therapy, is presenting data from its pivotal IGNYTE-ESO trial of lete-cel (letetresgene autoleucel), an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS) at the American Society of Clinical Oncology's (ASCO) annual meeting. Dr. Sandra D'Angelo of the Memorial Sloan Kettering Cancer Center will present "Lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma: Planned interim analysis of the pivotal IGNYTE-ESO trial" in an oral session at 11:30 a.m.
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications
Mechelen, Belgium and Philadelphia, PA, U.S. and Oxford, UK; 30 May 2024 22:01 CET; regulated information – inside information – Galapagos NV (Euronext & NASDAQ: GLPG) and Adaptimmune Therapeutics plc (Nasdaq: ADAP) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
Adaptimmune and Galapagos Sign Clinical Collaboration Agreement with an Option to Exclusively License Adaptimmune's TCR T-cell Therapy Candidate, uza-cel, in Head & Neck Cancer and Potential Future Solid Tumor Indications
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune's centralized manufacturing platform Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications Adaptimmune will hold a conference call tomorrow (May 31 st ) at 8 a.m. EDT (webcast link here and more details below) Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - May 30, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), and Galapagos NV (NA: GLPG) (NASDAQ: GLPG) announced today that they have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) targeting MAGE-A4 for head & neck cancer and potential future solid tumor indications, using Galapagos' decentralized cell manufacturing platform.
Adaptimmune Therapeutics plc (ADAP) Q1 2024 Earnings Call Transcript
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q1 2024 Earnings Conference Call May 15, 2024 8:00 AM ET Company Participants Juli Miller - Investor Relations Adrian Rawcliffe - Chief Executive Officer Gavin Wood - Chief Financial Officer Dennis Williams - Head of Late Stage Development Cintia Piccina - Chief Commercial Officer John Lunger - Chief Patient Supply Officer Elliot Norry - Chief Medical Officer Conference Call Participants Jonathan Chang - Leerink Partners Marc Frahm - TD Cowen Tony Butler - Rodman & Renshaw Graig Suvannavejh - Mizuho Securities Arthur He - H.C. Wainwright Peter Lawson - Barclays Operator Good morning, ladies and gentlemen, and welcome to the Adaptimmune Q1 2024 Financial and Business Update Conference Call.
Adaptimmune Reports Q1 2024 Financial and Business Updates
Afami-cel commercial and regulatory update presented at Company's Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024 Commercial and manufacturing infrastructure in place to support afami-cel commercial launch upon approval Data from SPEARHEAD-1 pivotal trial with afami-cel published in The Lancet; data from a planned interim analysis of pivotal lete-cel IGNYTE-ESO trial to be presented at ASCO Cash runway into late 2025 Conference call today at 8 a.m. EDT webcast link HERE Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today reports financial results and business updates for the first quarter ended March 31, 2024.
Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital
First tranche of $25 million available upon closing; the Company will be eligible to draw an additional $25 million subject to afami-cel approval Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that it has entered into a $125 million five-year, term loan facility with Hercules Capital, Inc. (NYSE: HTGC) ("Hercules"). The transaction strengthens the Company's balance sheet as it executes on its sarcoma franchise with the commercial launch of afami-cel later this year and lete-cel planned for 2026.
Adaptimmune to Report Q1 2024 Financial and Business Updates on Wednesday, May 15, 2024
Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 1, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, will report financial results and provide business updates for the first quarter ended March 31, 2024, before the US markets open on Wednesday, May 15, 2024. Following the announcement, the Company will host a live webcast at 8:00 a.m.
Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Their pipeline includes Afami-cel, which has shown promising results in solid tumors, and Lete-cel, targeting soft tissue sarcoma. Adaptimmune Therapeutics has a reasonable financial position with $144 million in cash, but the termination of a collaboration deal with Genentech poses a risk. Expenses will be an issue soon.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ADAP.